Swertiamarin suppresses proliferation, migration, and invasion of hepatocellular carcinoma cells via negative regulation of FRAT1

Submitted: 4 August 2020
Accepted: 30 September 2020
Published: 19 October 2020
Abstract Views: 692
PDF: 518
HTML: 5
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Studies have shown that swertiamarin (STM) has multiple biological activities, but its anti-tumour effects and molecular mechanisms are still unclear. The present research aimed to validate the STM’s impacts on the proliferation, migration, and invasion of hepatocellular carcinoma (HCC) cells, and to study its potential mechanism. Two HCC cell lines were treated with STM. Tumour growth was observed by the mouse tumour xenografts model. HCC cell lines stably expressing T-cell lymphomas 1 (FRAT1) were generated by lentivirusmediated overexpression. Cell viability, proliferation, migration, and invasion were observed using Cell Counting Kit-8 (CCK8), the xCELLigence Real-Time Cell Analyzer system (RTCA), and transwell analysis, respectively. Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting were used to observe the expression of FRAT1 and proteins related to the Wnt/β-catenin signalling pathway. Tumour growth was inhibited by STM in vivo. STM suppressed the proliferation, migration, and invasion of HCC cells. STM negatively regulated FRAT1 expression, whereas overexpressed FRAT1 blocked the anti-tumour function of STM. The results revealed that STM suppressed the FRAT1/Wnt/β-catenin signalling pathway. The findings of this study provide new insights into investigation of therapeutic strategies against HCC.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Ethics Approval

This study was approved by the Administration Committee of Experiment Animals of The Second Affiliated Hospital of Kunming Medical University

Supporting Agencies

Yunnan Hepatobiliary and Pancreatic Disease Clinical Center Fund, National Natural Science Foundation of China

How to Cite

Xiao, S., Tang, H., Bai, Y., Zou, R., Ren, Z., Wu, X., Shi, Z., Lan, S., Liu, W., Wu, T., Zhang, C., & Wang, L. (2020). Swertiamarin suppresses proliferation, migration, and invasion of hepatocellular carcinoma cells <em>via</em> negative regulation of FRAT1. European Journal of Histochemistry, 64(4). https://doi.org/10.4081/ejh.2020.3169